121 related articles for article (PubMed ID: 2402220)
1. The use of somatostatin analog in gastroenteropancreatic tumors other than carcinoid.
Vinik AI; Lloyd R; Cho K
Metabolism; 1990 Sep; 39(9 Suppl 2):156-62. PubMed ID: 2402220
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin analogue (SMS 201-995) in patients with gastrinomas.
Vinik AI; Tsai S; Moattari AR; Cheung P
Surgery; 1988 Nov; 104(5):834-42. PubMed ID: 2903562
[TBL] [Abstract][Full Text] [Related]
3. Long-acting somatostatin analog controls acid and gastrin secretion in benign, not in malignant, Zollinger-Ellison syndrome.
Bauer FE; Hummel M; Merki HS; Schulz E; Oeder R; Marbach P
J Clin Gastroenterol; 1989 Jun; 11(3):282-6. PubMed ID: 2754214
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes.
Vinik AI; Tsai ST; Moattari AR; Cheung P; Eckhauser FE; Cho K
Am J Med; 1986 Dec; 81(6B):23-40. PubMed ID: 2879447
[TBL] [Abstract][Full Text] [Related]
5. Prospective study of the antitumor efficacy of long-term octreotide treatment in patients with progressive metastatic gastrinoma.
Shojamanesh H; Gibril F; Louie A; Ojeaburu JV; Bashir S; Abou-Saif A; Jensen RT
Cancer; 2002 Jan; 94(2):331-43. PubMed ID: 11900219
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the in vivo and in vitro inhibition of gastrin secretion from gastrinoma by a somatostatin analogue (SMS 201-995).
Ellison EC; Gower WR; Elkhammas E; Woltering EA; Sparks J; O'Dorisio TM; Fabri PJ
Am J Med; 1986 Dec; 81(6B):56-64. PubMed ID: 2879448
[TBL] [Abstract][Full Text] [Related]
7. Effect of somatostatin analog on peptide release and tumor growth in the Zollinger-Ellison syndrome.
Mozell E; Woltering EA; O'Dorisio TM; Fletcher WS; Sinclair AJ; Hill D
Surg Gynecol Obstet; 1990 Jun; 170(6):476-84. PubMed ID: 2188384
[TBL] [Abstract][Full Text] [Related]
8. Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: implications for the treatment of apudomas.
Ellison EC; O'Dorisio TM; Sparks J; Mekhjian HS; Fromkes JJ; Woltering EA; Carey LC
Surgery; 1986 Aug; 100(2):437-44. PubMed ID: 2426819
[TBL] [Abstract][Full Text] [Related]
9. Effect of somatostatin analogue (octreotide) on blood flow to endocrine tumors metastatic to the liver: angiographic evaluation.
Cho KJ; Vinik AI
Radiology; 1990 Nov; 177(2):549-53. PubMed ID: 2171015
[TBL] [Abstract][Full Text] [Related]
10. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
11. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
Gorden P; Comi RJ; Maton PN; Go VL
Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688
[TBL] [Abstract][Full Text] [Related]
12. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors.
Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B
Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine tumours of the gut: long-term therapy with the somatostatin analogue SMS 201-995.
Anderson JV; Bloom SR
Scand J Gastroenterol Suppl; 1986; 119():115-28. PubMed ID: 2876495
[TBL] [Abstract][Full Text] [Related]
14. Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors.
Maton PN; Gardner JD; Jensen RT
Dig Dis Sci; 1989 Mar; 34(3 Suppl):28S-39S. PubMed ID: 2537716
[TBL] [Abstract][Full Text] [Related]
15. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
Williams G; Anderson JV; Williams SJ; Bloom SR
Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
[TBL] [Abstract][Full Text] [Related]
16. [Therapy of endocrine gastrointestinal-pancreatic tumors with somatostatin analog octreotide].
Arnold R; Neuhaus C; Trautmann ME
Dtsch Med Wochenschr; 1992 Jul; 117(27):1067-71. PubMed ID: 1352235
[No Abstract] [Full Text] [Related]
17. [Somatostatin receptor scintigraphy in preoperative diagnosis of the site of endocrine gastrointestinal tumors].
Weinel RJ; Kisker O; Joseph K; Welcke U; Zaraca F; Rothmund M
Chirurg; 1994 Oct; 65(10):849-55. PubMed ID: 7821043
[TBL] [Abstract][Full Text] [Related]
18. Effect of somatostatin analogue (SMS 201-995) on molecular species of gastrin in gastrinoma.
Campagnolo D; Gower WR; Fabri PJ; Sparks J; Mekhjian HS; O'Dorisio TM; Ellison EC
Surgery; 1987 Dec; 102(6):982-7. PubMed ID: 2891204
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment with SMS 201-995 of Cushing's syndrome caused by ectopic adrenocorticotropin secretion from a metastatic gastrin-secreting pancreatic islet cell carcinoma.
Lamberts SW; Tilanus HW; Klooswijk AI; Bruining HA; van der Lely AJ; de Jong FH
J Clin Endocrinol Metab; 1988 Nov; 67(5):1080-3. PubMed ID: 2846625
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory actions of a somatostatin analog SMS 201-995 on endocrine secretion from the isolated perfused stomach and pancreas of the rat.
Verchere CB; Kwok YN; Brown JC
Pharmacology; 1993; 46(1):50-60. PubMed ID: 8094569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
